Interleukin-16 as a marker of Sézary syndrome onset and stage

Jillian Richmond, Marina Tuzova, Ashley Parks, Natalie Adams, Elizabeth Martin, Marianne Tawa, Lynne Morrison, Keri Chaney, Thomas S. Kupper, Clara N Curiel, William Cruikshank

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction: Sézary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage. Methods: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation. Results: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sézary syndrome, indicating this loss is not reversible. Conclusions: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sézary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.

Original languageEnglish (US)
Pages (from-to)39-50
Number of pages12
JournalJournal of Clinical Immunology
Volume31
Issue number1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Interleukin-16
Cutaneous T-Cell Lymphoma
T-Lymphocytes
Interleukin-15
Chemotactic Factors
Immunoenzyme Techniques
Confocal Microscopy

Keywords

  • caspase 3
  • CD26
  • Cutaneous T cell lymphoma
  • interleukin-16
  • malignant T cells
  • Sézary syndrome

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Richmond, J., Tuzova, M., Parks, A., Adams, N., Martin, E., Tawa, M., ... Cruikshank, W. (2011). Interleukin-16 as a marker of Sézary syndrome onset and stage. Journal of Clinical Immunology, 31(1), 39-50. https://doi.org/10.1007/s10875-010-9464-8

Interleukin-16 as a marker of Sézary syndrome onset and stage. / Richmond, Jillian; Tuzova, Marina; Parks, Ashley; Adams, Natalie; Martin, Elizabeth; Tawa, Marianne; Morrison, Lynne; Chaney, Keri; Kupper, Thomas S.; Curiel, Clara N; Cruikshank, William.

In: Journal of Clinical Immunology, Vol. 31, No. 1, 02.2011, p. 39-50.

Research output: Contribution to journalArticle

Richmond, J, Tuzova, M, Parks, A, Adams, N, Martin, E, Tawa, M, Morrison, L, Chaney, K, Kupper, TS, Curiel, CN & Cruikshank, W 2011, 'Interleukin-16 as a marker of Sézary syndrome onset and stage', Journal of Clinical Immunology, vol. 31, no. 1, pp. 39-50. https://doi.org/10.1007/s10875-010-9464-8
Richmond J, Tuzova M, Parks A, Adams N, Martin E, Tawa M et al. Interleukin-16 as a marker of Sézary syndrome onset and stage. Journal of Clinical Immunology. 2011 Feb;31(1):39-50. https://doi.org/10.1007/s10875-010-9464-8
Richmond, Jillian ; Tuzova, Marina ; Parks, Ashley ; Adams, Natalie ; Martin, Elizabeth ; Tawa, Marianne ; Morrison, Lynne ; Chaney, Keri ; Kupper, Thomas S. ; Curiel, Clara N ; Cruikshank, William. / Interleukin-16 as a marker of Sézary syndrome onset and stage. In: Journal of Clinical Immunology. 2011 ; Vol. 31, No. 1. pp. 39-50.
@article{68a2acaa571848cb9c744833ff7c7dd2,
title = "Interleukin-16 as a marker of S{\'e}zary syndrome onset and stage",
abstract = "Introduction: S{\'e}zary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage. Methods: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation. Results: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of S{\'e}zary syndrome, indicating this loss is not reversible. Conclusions: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of S{\'e}zary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.",
keywords = "caspase 3, CD26, Cutaneous T cell lymphoma, interleukin-16, malignant T cells, S{\'e}zary syndrome",
author = "Jillian Richmond and Marina Tuzova and Ashley Parks and Natalie Adams and Elizabeth Martin and Marianne Tawa and Lynne Morrison and Keri Chaney and Kupper, {Thomas S.} and Curiel, {Clara N} and William Cruikshank",
year = "2011",
month = "2",
doi = "10.1007/s10875-010-9464-8",
language = "English (US)",
volume = "31",
pages = "39--50",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Interleukin-16 as a marker of Sézary syndrome onset and stage

AU - Richmond, Jillian

AU - Tuzova, Marina

AU - Parks, Ashley

AU - Adams, Natalie

AU - Martin, Elizabeth

AU - Tawa, Marianne

AU - Morrison, Lynne

AU - Chaney, Keri

AU - Kupper, Thomas S.

AU - Curiel, Clara N

AU - Cruikshank, William

PY - 2011/2

Y1 - 2011/2

N2 - Introduction: Sézary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage. Methods: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation. Results: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sézary syndrome, indicating this loss is not reversible. Conclusions: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sézary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.

AB - Introduction: Sézary syndrome is one of the most common forms of cutaneous T cell lymphoma (CTCL). It is characterized by skin infiltration of malignant T cells. We examined interleukin-16, a potent T cell chemoattractant and cell-cycle regulator, as a prospective marker of disease onset and stage. Methods: The correlation of total intracellular interleukin-16 and surface CD26 was studied by flow cytometry. Confocal microscopy was performed to determine localization of interleukin-16 at different stages of the disease. The levels of interleukin-16 in plasma and culture supernatants were examined by enzyme-linked immunoassay. Additionally, lymphocytes from stage IB patients were cultured in the presence of interleukin-16 alone and in combination with interleukin-15, and their ability to survive and proliferate was determined by cell counts and [3H]TdR incorporation. Results: The data indicate that loss of both nuclear and intracellular pro-interleukin-16 highly correspond to disease stage, with a concomitant increase in secreted mature interleukin-16 in both culture supernatants and patients' plasma that peaks at stage IB. Loss of intracellular interleukin-16 strongly corresponded to loss of surface CD26, which has been shown to occur with more advanced stage of CTCL. Nuclear translocation of pro-interleukin-16 was not observed in late stages of Sézary syndrome, indicating this loss is not reversible. Conclusions: We propose that it is feasible to use plasma levels of IL-16 as a potential diagnostic marker of Sézary syndrome and to use loss of intracellular IL-16 as a prognostic indicator of disease severity and stage.

KW - caspase 3

KW - CD26

KW - Cutaneous T cell lymphoma

KW - interleukin-16

KW - malignant T cells

KW - Sézary syndrome

UR - http://www.scopus.com/inward/record.url?scp=79953906721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953906721&partnerID=8YFLogxK

U2 - 10.1007/s10875-010-9464-8

DO - 10.1007/s10875-010-9464-8

M3 - Article

C2 - 20878214

AN - SCOPUS:79953906721

VL - 31

SP - 39

EP - 50

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 1

ER -